Skip to content
OpenCapital
Get started

Innovate VATE Life Sciences — D&A

Other segment segments

Infrastructure
$2.9M-6.5%
Spectrum
$1.2M0.0%

Other financials

Income statement

See full
Revenue$364.8M+33.0%
Gross profit$53.5M+17.6%
Operating income$10.0M+194%
Net income-$16.8M+31.4%
EPS (diluted)-$1.29+31.7%

Balance sheet

See full
Cash & equivalents$134.6M+297%
Total debt$1.4B+11.6%
Total equity-$256.3M-25.5%
Total assets$936.8M+7.9%

Cash flow

See full
Operating cash flow$45.5M+423%
CapEx$200.0K-95.7%
Free cash flow$45.3M+341%

Valuation

See full
Market cap$254.69M+274%

Where this comes from

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innovate's life sciences — d&a.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innovate's life sciences — D&A?
Innovate (VATE) reported life sciences — D&A of $100K in Q1 2026.
How has Innovate's life sciences — D&A changed year-over-year?
Innovate's life sciences — D&A decreased by 0.0% year-over-year, from $100K to $100K.
What is the long-term trend for Innovate's life sciences — D&A?
Over 4 years (2021 to 2025), Innovate's life sciences — D&A has grown at a 18.9% compound annual growth rate (CAGR), from $200K to $400K.
What does life sciences — D&A mean?
This represents the systematic allocation of the cost of tangible and intangible assets over their useful lives within the Life Sciences segment. It provides a view of the segment's capital intensity and the non-cash impact of asset aging on reported earnings.